Pomerantz LLP investigates Valneva SE over alleged securities fraud claims.

Pomerantz LLP is investigating claims of securities fraud against Valneva SE, a vaccine manufacturer, following reports of five hospitalizations for cardiac or neurologic events after vaccination with its chikungunya virus vaccine. The CDC is currently investigating the incidents, and Valneva's ADR price fell 13.57% after the announcement. Investors who held Valneva shares are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Pomerantz LLP, a renowned law firm specializing in corporate, securities, and antitrust class litigation, has initiated an investigation into claims of securities fraud against Valneva SE (NASDAQ: VALN), a vaccine manufacturer. The investigation follows reports of five hospitalizations for cardiac or neurologic events after vaccination with Valneva's chikungunya virus vaccine, IXCHIQ. The U.S. Centers for Disease Control and Prevention (CDC) is currently investigating these incidents.

On February 25, 2025, the CDC posted a notice on its website announcing the hospitalizations. Following this announcement and subsequent media reporting, Valneva's American Depositary Receipt (ADR) price fell by $1.06 per ADR, or 13.57%, over the following four trading sessions, closing at $6.75 per ADR on February 28, 2025 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN^[1].

On August 22, 2025, the U.S. Food and Drug Administration (FDA) announced that it had suspended the marketing application for IXCHIQ due to safety concerns. This news led to a further decline in Valneva's ADR price, falling by $2.21 per ADR, or 18.99%, to close at $9.43 per ADR on August 25, 2025 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN^[1].

Investors who held Valneva shares are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information about the investigation.

Valneva, headquartered in Switzerland, specializes in developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases. The company has a strong track record in advancing vaccines from early research and development to approvals. However, the recent developments have raised concerns among investors and regulatory bodies.

Pomerantz LLP, founded by Abraham L. Pomerantz, has a long history of recovering multimillion-dollar damages on behalf of class members in securities fraud cases. The firm's current investigation into Valneva aims to protect the interests of investors who may have been affected by potential securities fraud Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN^[1].